Now showing items 1-2 of 2

    • LTX-315: a first-in-class oncolytic peptide that reprograms the tumor microenvironment 

      Sveinbjørnsson, Baldur; Camilio, Ketil Andre; Haug, Bengt Erik; Rekdal, Øystein (Future Science, 2017)
      The oncolytic peptide LTX-315, which has been de novo designed based on structure–activity relationship studies of host defense peptides, has the ability to kill human cancer cells and induce specific anticancer immune ...
      Journal article
    • Oncolytic peptide LTX-315 induces an immune-mediated abscopal effect in a rat sarcoma model 

      Nestvold, Janne M.; Wang, Mengyu; Camilio, Ketil Andre; Zinöcker, Severin; Tjelle, Torunn Elisabeth; Lindberg, Alf; Haug, Bengt Erik; Kvalheim, Gunnar; Sveinbjørnsson, Baldur; Rekdal, Øystein (Taylor & Francis, 2017)
      LTX 315 is an oncolytic peptide with potent immunological properties. In the present study, we demonstrate that intratumoral treatment with LTX-315 resulted in a complete regression and systemic immune response in a rat ...
      Journal article